J&J, Novoste Receive Simultaneous Approval For Brachytherapy Devices
This article was originally published in The Gray Sheet
Executive Summary
FDA's Nov. 3 approval of Novoste's Beta-Cath and Johnson & Johnson/Cordis' Checkmate intravascular brachytherapy systems for treating in-stent restenosis come in time for the firms to unveil their devices at the upcoming American Heart Association scientific sessions, scheduled for Nov. 12-15 in New Orleans.
You may also be interested in...
Novoste Looking For “Deal-Maker” As CEO Hawkins Moves To Medtronic
Novoste will shift focus from leveraging core technologies and building a sales infrastructure to diversification and growth following the departure of CEO and President Bill Hawkins in mid-January to head Medtronic's vascular unit, Medtronic AVE
Novoste Looking For “Deal-Maker” As CEO Hawkins Moves To Medtronic
Novoste will shift focus from leveraging core technologies and building a sales infrastructure to diversification and growth following the departure of CEO and President Bill Hawkins in mid-January to head Medtronic's vascular unit, Medtronic AVE
Novoste Parrying Drug-Coated Stents With Planned Indications For Beta-Cath
Novoste will rely on supplemental indications unaddressed by drug-coated stent developers to increase adoption of its Beta-Cath vascular brachytherapy system.